FINACEA

FINACEA is the first and only gel approved by the FDA to treat bumps, pimples, and redness associated with mild to moderate rosacea.

FINACEA starts working quickly and keeps working

Some patients who used FINACEA saw their symptoms improve in as early as 4 weeks.
Continued use of FINACEA will help you maintain improvements over time.

The active ingredient of FINACEA is naturally occurring

FINACEA contains azaleic acid (AzA), a safe, naturally occuring ingredient. It comes in a water-based gel free of fragrance or alcohol and helps to limit allergic reaction and dryness

FINACEA may help improve your skin's appearance

AzA, the active ingredient of FINACEA, has anti-infiammatory, antioxidant and germ killing properties.
AzA helps reduce skin thickness, even skin tone and improve skins appearance.

FINACEA is here to help

Receive emails with important imformation that will help you take control of managing your rosacea along with occasional promotions!

Save $10

Try it today!

Already using
FINACEA?

INDICATION & USAGE

FINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

IMPORTANT SAFETY INFORMATION

FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.

Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.

Intendis, Inc. reserves the right to terminate or modify this program at its sole discretion and without notice.

Home Prescribing information Terms of Use Privacy Policy About Intendis Contact us